Germany’s science and technology company Merck KGaA today announced its investment in SynSense (formerly known as aiCTX), a neuromorphic computing start-up based in China and Switzerland. 6 May 2020
Danish drugmaker Acesion Pharma, which is focused on novel treatments for atrial fibrillation (AF), has recruited Anders Gaarsdal Holst as its chief medical officer (CMO) to succeed Nils Edvardsson, who will continue to support the company as medical adviser. 6 May 2020
The US District Court in Delaware issued a decision upholding the validity of patent claims from three patents that protect Amgen's multiple myeloma therapy Kyprolis (carfilzomib). 5 May 2020
French vaccines startup Vaxxel has bought Transgene’s proprietary DuckCelt-T17 cell line, technology relevant to a variety of viruses, including flu and human metapneumoviruses. 4 May 2020
Switzerland-based Actelion has presented new trial results on the effects of Opsumit (macitentan) on right ventricular (RV) remodelling in pulmonary arterial hypertension (PAH). 1 May 2020
Puma Biotechnology and Bixink Therapeutics, a new South Korean company working in the field of anti-cancer drugs and digital therapeutics, have entered into an exclusive agreement under which Bixink will commercialize Nerlynx (neratinib) in South Korea. 1 May 2020
Despite recent setbacks in Chinese clinical trials, Japan’s Prime Minister Shinzo Abe said Monday, during a parliamentary session, that Japan will soon approve the anti-viral drug remdesivir for the treatment of coronavirus patients, in what will be the country's first such decision amid the pandemic, reported the local Kyoda News. 28 April 2020
Japan’s Takeda Pharmaceutical today announced that the US Food and Drug Administration has granted Breakthrough Therapy designation for its investigational drug mobocertinib (formerly known as TAK-788). 27 April 2020
Israel’s Teva Pharmaceutical Industries today announced the availability of an autoinjector device for Ajovy fremanezumab-vfrm), a preventive treatment of migraine in adults that thus far was available as a pre-filled syringe. 27 April 2020
UK-based biotech Touchlight has appointed Helen Horton, formerly a senior scientific director at Johnson & Johnson, as chief research officer. 27 April 2020
Takeda Pharmaceutical has entered into an agreement to divest a portfolio of select non-core over-the-counter (OTC) and prescription pharmaceutical products sold in Europe, and two manufacturing sites located in Denmark and Poland to Danish company Orifarm Group. 25 April 2020
Novartis today announced that the US Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kymriah (tisagenlecleucel), for an investigational new indication to treat patients with relapsed or refractory (r/r) follicular lymphoma (FL). 22 April 2020
Law firm BakerHostetler has issued a report reviewing the US Food and Drug Administration's stance on Current Good Manufacturing Practice (cGMP) regulations, in light of the COVID-19 pandemic. 22 April 2020
China plans to introduce an early resolution mechanism, such as patent linkage, for drug patent disputes by the end of October this year, according to China’s intellectual property administration. 22 April 2020
Denmark-based allergy immunotherapy specialist ALK Abello today announced that Health Canada has approved once-daily Itulatek (standardized allergen extract, white birch [betula verrucose] sublingual tablet) for the treatment of tree pollen allergy. 20 April 2020
Aceto, a US virtual manufacturer of specialty materials for life sciences, nutrition, agricultural, and advanced technology end markets and a New Mountain Capital portfolio company, announced its acquisition of UK-based Syntor Fine Chemicals on Friday. 18 April 2020
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has confirmed that Picato (ingenol mebutate), a gel for treating the skin condition actinic keratosis, may increase the risk of skin cancer and concluded that the risks of the medicine outweigh its benefits. 17 April 2020
Sir Andrew Witty has been asked to co-lead a global effort of the World Health Organization (WHO), in partnership with key stakeholders, to accelerate the development of a COVID-19 vaccine. 16 April 2020
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
The European Medicines Agency’s pharmacovigilance committee, PRAC, has started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviors. 4 October 2024
Opioid Use Disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs and prolonged self-administration of opioid drugs. 4 October 2024
Proposals from the National Health Service (NHS) England have been set out for a phased launch of Eli Lilly’s obesity injection Mounjaro/Zepbound (tirzepatide) at the start of a consultation. 4 October 2024
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. 3 October 2024
Israel’s Teva Pharmaceutical Industries and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a global licensing deal for the development of an anti PD-1 oncology biosimilar candidate. 3 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024